Sequence 13 from Patent US 20020137896

General Information


DRACP ID  DRACP01214

Peptide Name   Sequence 13 from Patent US 20020137896

Sequence  ADPRVVVDLRFFGKSDIVEENRVTFGPNPK

Sequence Length  30

UniProt ID  Q8J2V8 

PubChem CID  Not available

Origin  Synthetic construct

Type  Native peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Antitumor



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01214

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C153H241N43O45

Absent amino acids  CHMQWY

Common amino acids  V

Mass  392029

Pl  6.66

Basic residues  5

Acidic residues  5

Hydrophobic residues  11

Net charge  0

Boman Index  -7222

Hydrophobicity  -44.67

Aliphatic Index  77.67

Half Life 
  Mammalian: 30 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  6

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2002/0137896 A1

Patent Title  Antitumor protein and gene encoding same.

Other Iinformation  Granted Patent Family: 3s / 5ex; Family Jurisdictions: US; Legal Status: Expired; Application No: 91196901; Filed:Jul 24, 2001; Published: Sep 26, 2002; Earliest Priority: Feb 13, 1997; Granted: Jul 13, 2004

Other Published ID  US6291648  US6762296 




DRACP is developed by Dr.Zheng's team.